Shares of Sarepta (NASDAQ:SRPT) were trading down 5%, after the company released its 62-week look at its Duchenne muscular dystrophy drug Eteplirsen. The company's 48-week look at the drug produced results that indicated the drug may revolutionize the way we treat the disease, as it not only slowed DMD's progression, it actually lengthened the distance patients were able to walk. The 62-week results were also good, but, perhaps, the market was expecting a miracle after what it saw at the 48-week mark. Sarepta stock jumped up 26% in November for a colossal 550% for the year.
David Williamson has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.